Two years after issuing a refuse to file (RTF) letter to Y-mAbs regarding Omblastys (omburtamab), the FDA has agreed to hear data supporting the development of the radioisotope-linked antibody designed to deliver targeted radiation to tough-to-treat pediatric brain tumors.
Source: Drug Industry Daily